NI201300008A - El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional - Google Patents

El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional

Info

Publication number
NI201300008A
NI201300008A NI201300008A NI201300008A NI201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A NI 201300008 A NI201300008 A NI 201300008A
Authority
NI
Nicaragua
Prior art keywords
conjugate
formula
polyethylene glycol
interferon
represented
Prior art date
Application number
NI201300008A
Other languages
English (en)
Inventor
Veniaminovna Chernovskaya Tatyana
Alexandrovich Denisov Lev
Valentinovich Morozov Dmitriy
Georgievna Rudenko Elena
Vsevolodovna Klenova Angelina
Original Assignee
Closed Join Stock Company Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300008(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Closed Join Stock Company Biocad filed Critical Closed Join Stock Company Biocad
Publication of NI201300008A publication Critical patent/NI201300008A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención está relacionada a la industria farmacéutica y medicina, en particular, al nuevo PEG - interferón derivados y al descubrimiento de un conjugado nuevo funcional, altamente estable de interferón a polietileno glicol con una actividad interferón alfa, con inmunogenicidad reducida, con efectos biológicos prolongados y parámetros fármaco - kinéticos mejorados de fórmula general (I). También la invención está relacionada a drogas conteniendo el declarado conjugado de la fórmula (1), composiciones farmacéuticas conteniendo PEG - IFN conjugado y terapéuticamente aceptable excipientes ideales para el tratamiento de infecciones virales y cáncer, también enfermedades asociadas con inmunodeficiencia primaria o secundaria. La invención está relacionada al uso de conjugado de fórmula (1) en productos medicinales, los cuales tienen actividad antiviral, antiproliferativa e inmunomodulatoria, aproximaciones y/o tratamiento de enfermedades asociadas con inmunodeficiencia primaria o secundaria de conjugado de fórmula (1) y al contenedor con tal composición farmacéutica.
NI201300008A 2010-07-20 2013-01-18 El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional NI201300008A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (ru) 2010-07-20 2010-07-20 НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Publications (1)

Publication Number Publication Date
NI201300008A true NI201300008A (es) 2014-05-26

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300008A NI201300008A (es) 2010-07-20 2013-01-18 El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional

Country Status (20)

Country Link
KR (1) KR101586372B1 (es)
CN (1) CN102617736B (es)
AR (1) AR087227A1 (es)
BR (1) BRPI1101565A2 (es)
CO (1) CO6680611A2 (es)
CR (1) CR20130021A (es)
CU (1) CU24193B1 (es)
DO (1) DOP2013000002A (es)
EA (1) EA020257B1 (es)
EC (1) ECSP13012398A (es)
HK (1) HK1170504A1 (es)
MX (1) MX2011007458A (es)
MY (1) MY168784A (es)
NI (1) NI201300008A (es)
PE (1) PE20131034A1 (es)
RU (1) RU2447083C1 (es)
SG (1) SG187117A1 (es)
UA (1) UA99766C2 (es)
UY (1) UY33525A (es)
WO (1) WO2012011836A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (ru) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ)
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
EA029498B1 (ru) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
EP4139343A4 (en) * 2020-04-20 2024-06-12 National Research Council of Canada RECOMBINANT INTERFERON
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
MXPA05002620A (es) * 2002-09-09 2005-05-05 Nektar Therapeutics Al Corp Alcanales polimericos solubles en agua.
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
JP5600240B2 (ja) * 2005-07-19 2014-10-01 ウェルズ ファーゴ バンク ナショナル アソシエイション 重合体マレイミド類を調製する方法
WO2007149594A2 (en) * 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
CN101491682A (zh) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101591387A (zh) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 聚乙二醇化重组人干扰素ω偶合物
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
RU2010129824A (ru) 2012-01-27
UY33525A (es) 2012-02-29
SG187117A1 (en) 2013-02-28
DOP2013000002A (es) 2013-09-15
EA201100809A1 (ru) 2012-01-30
WO2012011836A1 (en) 2012-01-26
ECSP13012398A (es) 2013-05-31
CU24193B1 (es) 2016-09-30
BRPI1101565A2 (pt) 2012-12-04
UA99766C2 (uk) 2012-09-25
CO6680611A2 (es) 2013-05-31
CN102617736A (zh) 2012-08-01
KR101586372B1 (ko) 2016-01-18
KR20130056885A (ko) 2013-05-30
CU20130013A7 (es) 2013-04-19
HK1170504A1 (zh) 2013-03-01
CR20130021A (es) 2013-02-20
AR087227A1 (es) 2014-03-12
MY168784A (en) 2018-12-04
CN102617736B (zh) 2015-11-25
PE20131034A1 (es) 2013-09-27
RU2447083C1 (ru) 2012-04-10
MX2011007458A (es) 2012-01-19
EA020257B1 (ru) 2014-09-30

Similar Documents

Publication Publication Date Title
NI201300008A (es) El nuevo estable polietileno glicol conjugado de interferon alfa, representado por un isómero posicional
DOP2011000343A (es) Derivados de piridina tieno [2,3-b] como inhibidores de replicacion viral
NI201700101A (es) Composiciones farmacéuticas que comprenden n - (3, 5 - dimetoxifenil) - n'- (1-metiletil) - n - [3-(1-metil-1h-pirazol-4-il) quinoxalina-6-il]etano-1,2-diamina
MX2022013596A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
NZ741957A (en) Therapeutic compositions for treatment of human immunodeficiency virus
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
SI2932970T1 (en) Antiviral therapy
MD4430B1 (ro) Compoziţii şi metode de tratament al hepatitei virale C
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
JP2013542247A5 (es)
UY29085A1 (es) Derivados de pirimidina 4-sulfonamido sustituidos, compuestos intermedios para su preparación, procedimientos de preparación, composiciones medicinales conteniéndolos y aplicaci0nes
BR112015007366A2 (pt) derivados de acilaminopirimidina para o tratamento de infecções virais e outras doenças
EA200800467A1 (ru) Применение сложных эфиров гидроксибензойной кислоты и аналогов для получения лекарственного средства для предупреждения и лечения вирусной инфекции
CR20140540A (es) Nueva forma de dosificación y formulación de abediterol
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
BR112022010574A2 (pt) Composições farmacêuticas compreendendo cabotegravir
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
AR093476A1 (es) Composiciones y metodos para el tratamiento de la displasia ectodermica
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
MX2014005960A (es) Compuestos de anillo fusionado que contienen nitrogeno como antagonistas crth2.
TH133837A (es)
CO2020000292A2 (es) Preparación medicinal combinada para tratar infecciones virales
RU2014116988A (ru) Алиспоривир для лечения инфекции, вызванной вирусом гепатита с